Peking University is conducting a multicenter study looking at the efficacy and safety of using Teriflunomide, an immune modulator, in combination with a weak androgen and anabolic steroid called Danazol to treat adults with steroid-resistant or returning ITP. Eligible participants must be at least 18-80 years with primary ITP with a platelet count less than 30,000 or less than 50,000 with bleeding symptoms.
China
Actively Recruiting